(Total Views: 460)
Posted On: 11/21/2024 9:01:22 PM
Post# of 148863
Looks like you found it…from our initial PR of FDA approval…
“Leronlimab will be administered weekly, while TAS-102 and bevacizumab will be given on a 3- or 4-week schedule within a 4-week cycle.”
The MAB will be weekly, the chemos will be at the usual toleration rate.
Investors Hangout: https://investorshangout.com/post/view?id=673...z8sGrjiKZ5
“Leronlimab will be administered weekly, while TAS-102 and bevacizumab will be given on a 3- or 4-week schedule within a 4-week cycle.”
The MAB will be weekly, the chemos will be at the usual toleration rate.
Investors Hangout: https://investorshangout.com/post/view?id=673...z8sGrjiKZ5
(4)
(0)Scroll down for more posts ▼
